Loading
companiesCompany
Vironexis Biotherapeutics
Vironexis Biotherapeutics is a US-based biotechnology company that leads 2 cancer trials in OnCo, testing the AAV-delivered T-cell engager gene therapies VNX-101 and VNX-202 in acute lymphoblastic leukaemia, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia, non-Hodgkin lymphoma and advanced solid tumours.
Also called: Vironexis Biotherapeutics Inc.
Overview
Vironexis Biotherapeutics is a clinical-stage biotechnology company developing AAV-delivered, in vivo T-cell engager gene therapies on its TransJoin platform, given as a single intravenous dose. Its lead programme VNX-101 is in phase 1/2 for CD19-positive leukaemias and lymphomas, with VNX-202 for HER2-positive cancers. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT06533579 (phase 1/2, Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)) and NCT07192432 (phase 1/2, Gene Therapy for HER-Positive Cancer (SENTRY-HER2)). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.